Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: j_fir2 who wrote (3378)	6/29/1999 5:09:00 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) \| Respond to of 10280

Hi j'fir, <One thing I don't recall knowing is that (r)(r) fluoxetine, the single isomer of the active metabolite of Prozac (a seretonin reuptake inhibitor) is also a norepinephrine and dopamine reuptake inhibitor.> Not only did you not know but it seems to be in conflict with other statements by the company. One example, "... studies indicate that (+)desmethylsibutramine may be a potent selective serotonin reuptake inhibitor (SSRI), norepinephrine and dopamine reuptake inhibitor. This UNIQUE triple mechanism of action may offer other benefits ..." Can anyone shed more light on this? Or will we have to wait for the studies to be made public before we will really understand? ij